Synergism of Proneurogenic miRNAs Provides a More Effective Strategy to Target Glioma Stem Cells.

glioblastoma miR-124 miR-128 miR-137 miRNA neuroblastoma

Journal

Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829

Informations de publication

Date de publication:
14 Jan 2021
Historique:
received: 14 12 2020
revised: 08 01 2021
accepted: 11 01 2021
entrez: 20 1 2021
pubmed: 21 1 2021
medline: 21 1 2021
Statut: epublish

Résumé

Tumor suppressor microRNAs (miRNAs) have been explored as agents to target cancer stem cells. Most strategies use a single miRNA mimic and present many disadvantages, such as the amount of reagent required and the diluted effect on target genes. miRNAs work in a cooperative fashion to regulate distinct biological processes and pathways. Therefore, we propose that miRNA combinations could provide more efficient ways to target cancer stem cells. We have previously shown that miR-124, miR-128, and miR-137 function synergistically to regulate neurogenesis. We used a combination of these three miRNAs to treat glioma stem cells and showed that this treatment was much more effective than single miRNAs in disrupting cell proliferation and survival and promoting differentiation and response to radiation. Transcriptomic analyses indicated that transcription regulation, angiogenesis, metabolism, and neuronal differentiation are among the main biological processes affected by transfection of this miRNA combination. In conclusion, we demonstrated the value of using combinations of neurogenic miRNAs to disrupt cancer phenotypes and glioma stem cell growth. The synergistic effect of these three miRNA amplified the repression of oncogenic factors and the effect on cancer relevant pathways. Future therapeutic approaches would benefit from utilizing miRNA combinations, especially when targeting cancer-initiating cell populations.

Identifiants

pubmed: 33466745
pii: cancers13020289
doi: 10.3390/cancers13020289
pmc: PMC7831004
pii:
doi:

Types de publication

Journal Article

Langues

eng

Subventions

Organisme : NHGRI NIH HHS
ID : R01 HG006015
Pays : United States
Organisme : NIH HHS
ID : 1 R21 NS113344-01A1
Pays : United States
Organisme : NIH HHS
ID : S10 OD021805
Pays : United States
Organisme : Owens Foundation
ID : NA
Organisme : NCI NIH HHS
ID : P30 CA054174
Pays : United States
Organisme : NINDS NIH HHS
ID : R21 NS113344
Pays : United States

Références

Pharmacol Res. 2019 Jan;139:395-411
pubmed: 30500458
Front Genet. 2013 Apr 26;4:58
pubmed: 23637704
Pharmacol Res Perspect. 2015 Jun;3(3):e00149
pubmed: 26171228
Onco Targets Ther. 2019 Feb 18;12:1269-1278
pubmed: 30863094
Mol Cancer Res. 2009 Aug;7(8):1234-43
pubmed: 19671678
Cancer Res. 2007 Feb 1;67(3):976-83
pubmed: 17283129
Mol Cancer Ther. 2012 Sep;11(9):1863-72
pubmed: 22772423
Cancers (Basel). 2017 Apr 12;9(4):
pubmed: 28417948
Mol Oncol. 2012 Dec;6(6):590-610
pubmed: 23102669
Endocrinology. 2003 Jun;144(6):2325-35
pubmed: 12746293
Nucleic Acids Res. 2014 Jul;42(12):7539-52
pubmed: 24875477
Brief Bioinform. 2019 Sep 27;20(5):1621-1638
pubmed: 29800060
Front Genet. 2019 May 16;10:478
pubmed: 31156715
Neuro Oncol. 2020 Oct 14;22(10):1439-1451
pubmed: 32328646
Nat Genet. 2015 Jun;47(6):569-76
pubmed: 25915600
J Cell Physiol. 2019 Jul;234(7):10671-10679
pubmed: 30480816
Cancer Res. 2016 Apr 15;76(8):2465-77
pubmed: 26896279
Biochem Cell Biol. 2016 Jun;94(3):247-55
pubmed: 27105323
Mol Oncol. 2014 Dec;8(8):1603-15
pubmed: 25017126
Cancer Res. 2008 Nov 15;68(22):9125-30
pubmed: 19010882
Chem Biol Drug Des. 2015 Oct;86(4):432-9
pubmed: 25777055
Genome Biol. 2012 Oct 03;13(10):R88
pubmed: 23034120
Nat Rev Drug Discov. 2010 Jan;9(1):57-67
pubmed: 20043028
Nucleic Acids Res. 2016 Jun 2;44(10):4684-702
pubmed: 26896797
Genes Dev. 2008 Sep 15;22(18):2535-49
pubmed: 18794350
Nat Neurosci. 2018 Dec;21(12):1784-1792
pubmed: 30455455
Cold Spring Harb Symp Quant Biol. 2006;71:181-8
pubmed: 17381295
PLoS One. 2011;6(9):e24248
pubmed: 21912681
Nucleic Acids Res. 2020 Jan 8;48(D1):D148-D154
pubmed: 31647101
Mol Genet Metab. 2003 Sep-Oct;80(1-2):272-80
pubmed: 14567977
Genome Biol. 2014;15(12):550
pubmed: 25516281
Nat Biotechnol. 2016 May;34(5):525-7
pubmed: 27043002
PLoS One. 2016 Apr 01;11(4):e0152792
pubmed: 27035433
Oncotarget. 2018 Apr 20;9(30):21478-21494
pubmed: 29765554
Nat Methods. 2011 Jul 10;8(8):671-6
pubmed: 21743461
Mol Cancer. 2011 May 16;10:55
pubmed: 21575235
Stem Cells. 2016 Jan;34(1):220-32
pubmed: 26369286
Noncoding RNA. 2020 Jun 03;6(2):
pubmed: 32503170
BMC Med. 2008 Jun 24;6:14
pubmed: 18577219
Oncotarget. 2017 Apr 4;8(14):22783-22799
pubmed: 28187000
Br J Cancer. 2017 Sep 26;117(7):1036-1047
pubmed: 28787434
Nat Biotechnol. 2020 Jun;38(6):675-678
pubmed: 32444850
Lancet Oncol. 2009 May;10(5):459-66
pubmed: 19269895
Front Mol Neurosci. 2019 Jan 29;12:9
pubmed: 30760980
Yale J Biol Med. 2016 Dec 23;89(4):513-525
pubmed: 28018142
Front Cell Neurosci. 2015 May 20;9:193
pubmed: 26041995
Int J Oncol. 2013 Jan;42(1):134-40
pubmed: 23135478
Int J Oncol. 2012 Jul;41(1):228-34
pubmed: 22470130
Mol Syst Biol. 2010 Apr 20;6:363
pubmed: 20404830
Mol Med Rep. 2019 Jan;19(1):345-361
pubmed: 30483774
Cancer Cell Int. 2019 Dec 27;19:357
pubmed: 31889909
BMC Bioinformatics. 2019 Dec 27;20(Suppl 23):613
pubmed: 31881825
Oncol Rep. 2017 Jan;37(1):555-562
pubmed: 27878295
PLoS One. 2011;6(7):e21800
pubmed: 21789182
Oncotarget. 2015 Mar 10;6(7):5204-16
pubmed: 25294817
F1000Res. 2015 Dec 30;4:1521
pubmed: 26925227
Clin Cancer Res. 2018 Feb 1;24(3):684-695
pubmed: 29138341
J Biol Chem. 1994 Mar 11;269(10):7756-63
pubmed: 8126002
Genome Res. 2003 Nov;13(11):2498-504
pubmed: 14597658
Neuro Oncol. 2017 Jan;19(1):139-141
pubmed: 28031383
Mol Med Rep. 2016 Dec;14(6):5253-5260
pubmed: 27779678
Nucleic Acids Res. 2019 Jan 8;47(D1):D135-D139
pubmed: 30371849
Cell. 2013 Oct 10;155(2):462-77
pubmed: 24120142
Cancer Res. 2011 Jan 15;71(2):404-12
pubmed: 21123453
Neurobiol Learn Mem. 2012 Jan;97(1):69-80
pubmed: 21982980
Methods Mol Biol. 2017;1652:3-35
pubmed: 28791631
Bioinformatics. 2020 Apr 15;36(8):2628-2629
pubmed: 31882993
Oncotarget. 2014 May 15;5(9):2499-512
pubmed: 24811707
Nature. 2008 Sep 4;455(7209):58-63
pubmed: 18668040
Nat Neurosci. 2019 Apr;22(4):545-555
pubmed: 30778149
Cell Differ. 1984 Jun;14(2):135-44
pubmed: 6467378
Mol Pharmacol. 2010 Jul;78(1):58-68
pubmed: 20385708
Nat Struct Mol Biol. 2011 Sep 11;18(10):1139-46
pubmed: 21909094
Proc Natl Acad Sci U S A. 2013 May 21;110(21):8644-9
pubmed: 23650391
Nat Rev Mol Cell Biol. 2019 Jan;20(1):21-37
pubmed: 30108335
Mol Oncol. 2015 Aug;9(7):1324-40
pubmed: 25864039
Nucleic Acids Res. 2019 Jan 8;47(D1):D607-D613
pubmed: 30476243
Dev Growth Differ. 2010 Aug;52(6):493-504
pubmed: 20608952
Gastroenterology. 2014 Jan;146(1):268-77.e18
pubmed: 24120476
Hum Mutat. 2009 Jul;30(7):1062-71
pubmed: 19370765
Theranostics. 2018 Jan 1;8(4):1106-1120
pubmed: 29464002
APMIS. 2016 Mar;124(3):169-74
pubmed: 26582084
Exp Neurol. 2011 Jan;227(1):172-9
pubmed: 21035445
Proc Natl Acad Sci U S A. 2018 Jul 24;115(30):E7222-E7230
pubmed: 29987030
Nucleic Acids Res. 2019 Sep 5;47(15):7753-7766
pubmed: 31340025
Mol Neurobiol. 2011 Dec;44(3):359-73
pubmed: 21969146
Bioinformatics. 2006 Jun 15;22(12):1540-2
pubmed: 16595560
N Engl J Med. 1999 Oct 14;341(16):1165-73
pubmed: 10519894
EMBO Mol Med. 2013 Aug;5(8):1196-212
pubmed: 23818228
PeerJ. 2017 Aug 14;5:e3682
pubmed: 28828274
Crit Rev Oncol Hematol. 2017 Dec;120:22-33
pubmed: 29198335
Int J Cancer. 2010 Nov 15;127(10):2374-85
pubmed: 20473924
Nucleic Acids Res. 2019 Jan 8;47(D1):D419-D426
pubmed: 30407594
Cell Death Dis. 2013 Apr 11;4:e586
pubmed: 23579273
Leuk Res. 2013 Oct;37(10):1315-21
pubmed: 23915977
PLoS One. 2014 Jan 27;9(1):e86469
pubmed: 24475125
Sci Rep. 2020 Jun 2;10(1):8979
pubmed: 32488114
Front Cell Neurosci. 2019 Dec 18;13:559
pubmed: 31920559
Mol Oncol. 2019 Jan;13(1):46-60
pubmed: 30430751
PLoS One. 2014 Jan 22;9(1):e85591
pubmed: 24465609
Cell. 2018 Feb 8;172(4):650-665
pubmed: 29425488
PLoS Comput Biol. 2012;8(7):e1002488
pubmed: 22829753
Nat Protoc. 2009;4(4):495-505
pubmed: 19300443
Science. 2014 Jan 10;343(6167):189-193
pubmed: 24336570
Hum Mol Genet. 2010 Oct 15;19(R2):R169-75
pubmed: 20805106
Elife. 2015 Aug 12;4:
pubmed: 26267216

Auteurs

Adam Kosti (A)

Greehey Children's Cancer Research Institute, University of Texas Health Science Center at San Antonio, San Antonio, TX 78229, USA.
Department of Cell Systems & Anatomy, University of Texas Health Science Center at San Antonio, San Antonio, TX 78229, USA.

Rodrigo Barreiro (R)

Greehey Children's Cancer Research Institute, University of Texas Health Science Center at San Antonio, San Antonio, TX 78229, USA.
Centro de Oncologia Molecular, Hospital Sirio-Libanes, São Paulo 01308-060, Brazil.
Departamento de Bioquimica, Instituto de Quimica-Universidade de São Paulo, São Paulo 05508-000, Brazil.

Gabriela D A Guardia (GDA)

Centro de Oncologia Molecular, Hospital Sirio-Libanes, São Paulo 01308-060, Brazil.

Shiva Ostadrahimi (S)

Greehey Children's Cancer Research Institute, University of Texas Health Science Center at San Antonio, San Antonio, TX 78229, USA.

Erzsebet Kokovay (E)

Department of Cell Systems & Anatomy, University of Texas Health Science Center at San Antonio, San Antonio, TX 78229, USA.

Alexander Pertsemlidis (A)

Greehey Children's Cancer Research Institute, University of Texas Health Science Center at San Antonio, San Antonio, TX 78229, USA.
Department of Pediatrics, University of Texas Health Science Center at San Antonio, San Antonio, TX 78229, USA.

Pedro A F Galante (PAF)

Centro de Oncologia Molecular, Hospital Sirio-Libanes, São Paulo 01308-060, Brazil.
Departamento de Bioquimica, Instituto de Quimica-Universidade de São Paulo, São Paulo 05508-000, Brazil.

Luiz O F Penalva (LOF)

Greehey Children's Cancer Research Institute, University of Texas Health Science Center at San Antonio, San Antonio, TX 78229, USA.
Department of Cell Systems & Anatomy, University of Texas Health Science Center at San Antonio, San Antonio, TX 78229, USA.

Classifications MeSH